Publications - 'O'
Publications 1051 - 1075 de 1113
| Titre | DOI |
|---|---|
|
Overshoots of adsorption kinetics during layer-by-layer polyelectrolyte film growth: Role of counterions C.C. Buron; C. Filiatre 2014 |
10.1016/j.jcis.2013.09.040 |
|
Overtreatment in elderly patients >= 75 years with type 2 diabetes and renal disease A. Penfornis; J.F. Blickle; B. Fiquet; S. Dejager 2014 |
|
|
Overtreatment in elderly patients >= 75 years with type 2 diabetes and renal disease A. Penfornis; J.F. Blickle; B. Fiquet; S. Dejager 2014 |
|
|
Overview and stellar statistics of the expected Gaia Catalogue using the Gaia Object Generator X. Luri; M. Palmer; F. Arenou; E. Masana; J. de Bruijne; E. Antiche; C. Babusiaux; R. Borrachero; P. Sartoretti; F. Julbe; Y. Isasi; O. Martinez; A.C. Robin; C. Reyle; C. Jordi; J.M. Carrasco 2014 |
10.1051/0004-6361/201423636 |
|
Overview of medical practices in wet AMD in France H. Masse; B. Wolff; A. Bonnabel; A. Bourhis; P.L. Cornut; F. De Bats; V. Gualino; J. Halfon; P. Koehrer; G. Souteyrand; M. Streho; S. Tick; J. Zerbib; C. Chartier 2016 |
10.1016/j.jfo.2015.10.001 |
|
Overview of Social Cognitive Dysfunctions in Rare Developmental Syndromes with Psychiatric Phenotype A. Morel; E. Peyroux; A. Leleu; E. Favre; N. Franck; C. Demily 2018 |
10.3389/fped.2018.00102 |
|
Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera V.Sankar Sivasankarapillai; R.Madhu Kuma Nair; A. Rahdar; S. Bungau; D.Carmen Zaha; L. Aleya; D.Mirela Tit 2020 |
10.1007/s11356-020-09028-0 |
|
Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera V.Sankar Sivasankarapillai; R.Madhu Kuma Nair; A. Rahdar; S. Bungau; D.Carmen Zaha; L. Aleya; D.Mirela Tit 2020 |
10.1007/s11356-020-09028-0, Early Access Date = {MAY 2020 |
|
Overview of the Meso-NH model version 5.4 and its applications C. Lac; J.P. Chaboureau; V. Masson; J.P. Pinty; P. Tulet; J. Escobar; M. Leriche; C. Barthe; B. Aouizerats; C. Augros; P. Aumond; F. Auguste; P. Bechtold; S. Berthet; S. Bielli; F. Bosseur; O. Caumont; J.M. Cohard; J. Colin; F. Couvreux; J. Cuxart; G. Delautier; T. Dauhut; V. Ducrocq; J.B. Filippi; D. Gazen; O. Geoffroy; F. Gheusi; R. Honnert; J.P. Lafore; C.Lebeaupin Brossier; Q. Libois; T. Lunet; C. Mari; T. Maric; P. Mascart; M. Moge; G. Molinie; O. Nuissier; F. Pantillon; P. Peyrille; J. Pergaud; E. Perraud; J. Pianezze; J.L. Redelsperger; D. Ricard; E. Richard; S. Riette; Q. Rodier; R. Schoetter; L. Seyfried; J. Stein; K. Suhre; M. Taufour; O. Thouron; S. Turner; A. Verrelle; B. Vie; F. Visentin; V. Vionnet; P. Wautelet 2018 |
10.5194/gmd-11-1929-2018 |
|
Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity C. Guenancia; O. Hachet; M. Aboutabl; N. Li; E. Rigal; Y. Cottin; L. Rochette; C. Vergely 2016 |
10.1007/s00280-016-2995-9 |
|
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials T. Aparicio; M. Ducreux; R. Faroux; E. Barbier; S. Manfredi; T. Lecomte; P.L. Etienne; L. Bedenne; J. Bennouna; J.M. Phelip; E. Francois; P. Michel; J.L. Legoux; M. Gasmi; G. Breysacher; P. Rougier; A. de Gramont; C. Lepage; O. Bouche; J.F. Seitz; F.F.C.D. Investigators 2018 |
10.1016/j.ejca.2018.03.031 |
|
Overweight, obesity and weight gain after breast cancer (BC): A prospective clinical study A. Di Meglio; M. El-Mouhebb; S. Michiels; L. Jones; M. Annonay; A. Zingarello; M. Matias; S. Everhard; A.L. Martin; P. Arveux; O. Tredan; P. Soulie; P.H. Cottu; A.H. Partridge; L. Del Mastro; J.A. Ligibel; F. Andre; I. Vaz-Luis 2018 |
|
|
Overweight, obesity and weight gain after breast cancer (BC): A prospective clinical study A. Di Meglio; M. El-Mouhebb; S. Michiels; L. Jones; M. Annonay; A. Zingarello; M. Matias; S. Everhard; A.L. Martin; P. Arveux; O. Tredan; P. Soulie; P.H. Cottu; A.H. Partridge; L. Del Mastro; J.A. Ligibel; F. Andre; I. Vaz-Luis 2018 |
|
|
Ovulation induction (OI) or intrauterine insemination (IUI) with gonadotropins in patients with polycystic ovary syndrome (PCOS): description of patients and triggering rates. The GLOBALE-SOPK study V. Isnard; P. Sagot; M. Pasquier; S. Frantz-Blancpain; S. Paillet 2017 |
|
|
Ovulation induction (OI) or intrauterine insemination (IUI) with gonadotropins in patients with polycystic ovary syndrome (PCOS): description of patients and triggering rates. The GLOBALE-SOPK study V. Isnard; P. Sagot; M. Pasquier; S. Frantz-Blancpain; S. Paillet 2017 |
|
|
Ownership identity and firm performance: Pre- andpost-crisisevidence from an African emerging market I. Jabbouri; R. Jabbouri 2021 |
10.1002/ijfe.2103 |
|
Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial B. Tessoulin; D. Chiron; C. Thieblemont; L. Oberic; K. Bouadballah; E. Gyan; G. Damaj; V. Ribrag; R. Gressin; P. Feugier; O. Casasnovas; H. Zerazhi; F. Lemonnier; H. Maisonneuve; C. Joubert; E. Van Den Neste; T. Lamy; H. Tilly; A. Moreau; O. Hermine; S. Le Gouill 2021 |
10.1038/s41409-020-01198-2 |
|
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST) S. Watson; C. de la Fouchardiere; S. Kim; R. Cohen; J.B. Bachet; C. Tournigand; J.M. Ferraz; M. Lefevre; D. Colin; M. Svrcek; A. Meurisse; C. Louvet 2019 |
10.1016/j.ejca.2018.11.006 |
|
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST) (vol 107, pg 46, 2019) S. Watson; C. de la Fouchardiere; S. Kim; R. Cohen; J.B. Bachet; C. Tournigand; J.M. Ferraz; M. Lefevre; D. Colin; M. Svrcek; A. Meurisse; C. Louvet 2019 |
10.1016/j.ejca.2019.06.004 |
|
Oxaliplatin, 5FU and nab-paclitaxel as neoadjuvant regimen in patients with resectable oesogastric adenocarcinoma: A GERCOR phase 2 study (FOXAGAST). S.Sophie Watson; C. de la Fouchardiere; S.Chong Hun Kim; R. Cohen; J.B. Bachet; C. Tournigand; J.M. Ferraz; M. Lefevre; D. Colin; M. Svrcek; A. Meurisse; C. Louvet 2018 |
10.1200/JCO.2018.36.15_suppl.4035 |
|
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial J. Taieb; J. Tabernero; E. Mini; F. Subtil; G. Folprecht; J.L. Van Laethem; J. Thaler; J. Bridgewater; L.Norgard Petersen; H. Blons; L. Collette; E. Van Cutsem; P. Rougier; R. Salazar; L. Bedenne; J.F. Emile; P. Laurent-Puig; C. Lepage 2014 |
10.1016/S1470-2045(14)70227-X |
|
Oxaliplatin-Induced Evans Syndrome: A Possible Dual Mechanism C. Rousseau; T.Ngoc Nguyen; J.Michel Rebibou; J.Noel Bastie; S. Audia; A. Darut-Jouve; M. Legendre 2020 |
10.1016/j.clcc.2019.11.001 |
|
Oxiapoptophagy: A type of cell death induced by some oxysterols T. Nury; A. Zarrouk; A. Yammine; J.J. Mackrill; A. Vejux; G. Lizard 2021 |
10.1111/bph.15173 |
|
Oxiapoptophagy: A type of cell death induced by some oxysterols T. Nury; A. Zarrouk; A. Yammine; J.J. Mackrill; A. Vejux; G. Lizard Submitted |
10.1111/bph.15173, Early Access Date = {JUL 2020 |
|
Oxidation in wine: Does expertise influence the perception? E. Franco-Luesma; C. Honore-Chedozeau; J. Ballester; D. Valentin 2019 |
10.1016/j.lwt.2019.108511 |